期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌内分泌治疗的进展 被引量：1

原文传递
导出
摘要 乳腺癌是女性常见的恶性肿瘤之一。法国里昂国际癌症研究机构公布的2002年全球癌症统计数据中，乳腺癌的新发病例达115万，仅次于肺癌，在女性恶性肿瘤中位居首位。近年来，乳腺癌的发病率呈不断上升的趋势，而死亡率却有所下降。这主要得益于早期的诊断及有效的综合治疗。内分泌治疗在乳腺癌的综合治疗中占有着重要的地位。本文就乳腺癌的内分泌治疗的进展作一综述。
作者 杨名添 连臻强
机构地区 华南肿瘤学国家重点实验室
出处 《中华乳腺病杂志（电子版）》 CAS 2007年第1期9-15,共7页 Chinese Journal of Breast Disease(Electronic Edition)
关键词 内分泌治疗 乳腺癌 女性恶性肿瘤 综合治疗 统计数据 研究机构 新发病例 发病率
分类号 R737.9 [医药卫生—肿瘤] R737.33 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1宋三泰,江泽飞.乳腺癌芳香化酶抑制剂治疗的现状与存在问题[J].中华肿瘤杂志,2005,27(8):510-512. 被引量：13
  • 2Sainsbury R.Ovarian ablation as a treatment for breast cancer[].Surgical Oncology.2003
  • 3Jakesz R,Hausmaninger H,Kubista E, et al.Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast[].Journal of Clinical Oncology.2002
  • 4Davidson N E,O’’’’Neill A M,Vukov A M, et al.Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188) [ J ][].Journal of Clinical Oncology.2005
  • 5Gradishar W.Landmark trials in endocrine adjuvant therapy for breast carcinoma[].Cancer.2006
  • 6Grana G.Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data[ J][].Journal of Surgical Oncology.2006
  • 7Doisneau Sixou SF,Sergio CM,Carroll JS,et al.Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells[].Endocrine Related Cancer.2003
  • 8Campos SM.Aromatase inhibitors for breast cancer in postmenopausal women[].The Oncologist.2004
  • 9Castigltone Gertsch M,0 IVeill A,Price KN,et al.Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer; a randomized trial[].J Nail Cancer Insl.2003
  • 10Bonneterre J,Thurlimann B,Robertson J F,et al.Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study[].Journal of Clinical Oncology.2000

二级参考文献11

  • 1Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclopohsphamide, methotrexate,and fluororacil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the zoladex early breast cancer research association study. J Clin Oncol,2002,20:4628-4635.
  • 2Mouridsen H, Gershanovich M,Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase Ⅲstudy of the international letrozole breast cancer group. J Clin Oncol,2001,19:2596-2606.
  • 3Bonneterre J, Thurlimann B, Robertson J. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol,2000,18:3748-3757.
  • 4Nabholtz J, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol,2000,18:3758-3767.
  • 5Paridaens R, Therasse P, Dirix L, et al. First line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients- A randomized phaseⅢ trial of the EORTC Breast Group. Proc Am Soc Clin Oncol,2004,23:6.
  • 6Eiermann W, Paepke S, Appfelstaedt J, et al. preoperative treatment of post-menopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol,2001,12:1527-1532.
  • 7Robertson JFR, Willsher PC,Cheung KL, et al. The Clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer,1997,33:1774-1779.
  • 8The ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoifen alone for adjuvant treatment of postmnopausal women with early breast cancer: first results of the ATAC randmised trial. Lancet,2002,359:2131-2139.
  • 9Goss PE, Lngle JM, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003,349:1793-1802.
  • 10Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med,2004,350:1080-1092.

共引文献12

同被引文献8

引证文献1

二级引证文献3

中华乳腺病杂志（电子版）
2007年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部